Having trouble accessing articles? Reset your cache.

Viramune XR nevirapine: Phase III data

In the double-blind, double-dummy, active-controlled Phase III VERxVE trial in 1,011 treatment-naïve HIV patients, once-daily 400 mg Viramune XR was non-inferior to twice-daily immediate-release

Read the full 246 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE